Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.57 - $0.99 $501 - $871
-880 Reduced 7.49%
10,867 $9,000
Q1 2023

May 09, 2023

SELL
$0.51 - $0.78 $3,191 - $4,880
-6,257 Reduced 34.75%
11,747 $7,000
Q4 2022

Feb 10, 2023

BUY
$0.47 - $17.22 $3,737 - $136,933
7,952 Added 79.11%
18,004 $10,000
Q3 2022

Nov 10, 2022

SELL
$0.74 - $15.01 $16,417 - $333,011
-22,186 Reduced 68.82%
10,052 $7,000
Q2 2022

Aug 15, 2022

BUY
$0.71 - $2.43 $9,262 - $31,701
13,046 Added 67.98%
32,238 $32,000
Q1 2022

May 12, 2022

SELL
$2.31 - $5.13 $11,591 - $25,742
-5,018 Reduced 20.73%
19,192 $46,000
Q4 2021

Feb 14, 2022

SELL
$4.45 - $8.09 $42,929 - $78,044
-9,647 Reduced 28.49%
24,210 $115,000
Q3 2021

Nov 15, 2021

SELL
$6.94 - $8.85 $89,144 - $113,678
-12,845 Reduced 27.5%
33,857 $265,000
Q2 2021

Aug 16, 2021

BUY
$7.45 - $16.27 $334,236 - $729,937
44,864 Added 2440.91%
46,702 $377,000
Q1 2021

May 17, 2021

SELL
$8.78 - $12.8 $69,037 - $100,646
-7,863 Reduced 81.05%
1,838 $21,000
Q4 2020

Feb 16, 2021

SELL
$1.08 - $8.2 $51,363 - $389,983
-47,559 Reduced 83.06%
9,701 $79,000
Q3 2020

Nov 16, 2020

BUY
$0.95 - $1.42 $54,397 - $81,309
57,260 New
57,260 $67,000
Q1 2020

May 15, 2020

SELL
$0.67 - $1.85 $609 - $1,681
-909 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$1.36 - $2.44 $922 - $1,654
678 Added 293.51%
909 $2,000
Q3 2019

Nov 05, 2019

BUY
$1.74 - $2.83 $401 - $653
231 New
231 $1,000
Q2 2019

Aug 13, 2019

SELL
$1.36 - $2.35 $408 - $705
-300 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$0.78 - $2.01 $10,949 - $28,216
-14,038 Reduced 97.91%
300 $1,000
Q4 2018

Feb 14, 2019

BUY
$0.62 - $2.25 $6,780 - $24,608
10,937 Added 321.58%
14,338 $10,000
Q3 2018

Nov 13, 2018

SELL
$1.38 - $1.94 $16,343 - $22,975
-11,843 Reduced 77.69%
3,401 $6,000
Q2 2018

Aug 15, 2018

BUY
$1.73 - $3.35 $26,372 - $51,067
15,244 New
15,244 $26,000

About CURIS INC


  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $409M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.